Aegis Life Inc. and its parent company Entos Pharmaceuticals Inc. (Entos) have entered into a grant agreement with the Bill & Melinda Gates Foundation in the area of infectious disease.
Researchers from the Hospital Universitari Vall d’Hebron and colleagues have reported on the development of Hybri, a hybrid recombinant bispecific fusion protein with immunosuppressive activity that consists of the extracellular domain (ECD) of human PD-L2 fused via a linker to the ECD of human CTLA-4, further fused to the Fc domain of human IgG.
Researchers from Zhejiang University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have reported the discovery of new phosphoinositide 3-kinase α (PI3Kα) inhibitors for the treatment of cancer.
Researchers have ameliorated both monogenic and complex inflammation-driven diseases through transplantation of hematopoietic stem cells with an inserted IL-1 receptor antagonist (IL-1RA) gene. The team showed that in animal models the transplanted cells worked better than monoclonal antibodies to reduce symptoms in systemic autoinflammatory diseases (SAIDs), a group of childhood-onset, lifelong diseases that vary in severity depending on the underlying mutation, but can be life-threatening.
Tscan Therapeutics Inc. has received IND clearance by the FDA for TSC-200-A0201, a T-cell receptor (TCR) T-cell therapy targeting human papillomavirus 16 (HPV16), an oncogenic virus responsible for some cervical cancers and head and neck squamous cell carcinomas.
Researchers at West China Hospital, Sichuan University have identified remimazolam derivatives reported to be useful for the treatment of sedation and as anesthetics.
Insilico Medicine Inc. has reported the development of ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors described as useful for the treatment of cancer.
Sanofi SA has prepared and tested isoxazolidines acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. As such, they are reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and incontinentia pigmenti.
RSS
